Atropos Health, a pioneer in transforming real-world clinical data into actionable real-world evidence (RWE), has announced a collaboration with Merck to accelerate evidence generation and analytics. Leveraging Atropos’ suite of tools, including GENEVA OS™, Green Button™, and ChatRWD™, the partnership will enable rapid cohort creation, advanced analytics, and publication-grade studies in less than 48 hours. Merck’s data science and RWE teams will collaborate closely with Atropos’ experts to produce fast, accurate insights that support decision-making and innovation.

Atropos Health provides access to the industry’s largest federated healthcare data network, with over 300 million patient records, ensuring partners can access fit-for-purpose real-world data (RWD) through tools like Alexandria™ and Forge™. These platforms allow users to replicate studies, generate novel insights, and accelerate research by transforming months-long processes into minutes with AI-driven solutions. Atropos also evaluates data quality with its Real World Fitness Score® for better reliability and relevance.

The announcement comes as Atropos continues to expand its generative AI capabilities, including the launch of ChatRWD™, which enables full observational studies in minutes. In May 2024, Atropos raised $33 million in funding led by Valtruis, with significant contributions from Cencora Ventures, McKesson Ventures, and Merck Global Health Innovation Fund, to support its mission of revolutionizing health data analytics.